Top 10 Fastest-Growing Biotech Stocks: HGSI, UTHR, CHBT, BMTI, SVA, ACOR, EXAS, INCY, NBIX, XNPT (Aug 31, 2010)

Below are the top 10 fastest-growing Biotechnology stocks, based on the average long-term earnings growth rate estimated by Wall Street analysts. Two Chinese companies (CHBT, SVA) are on the list.

Human Genome Sciences (NASDAQ:HGSI) is the 1st fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 106.7%. This number is based on the average estimate of 1 brokerage analyst(s). United Therapeutics Corporation (NASDAQ:UTHR) is the 2nd fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 67.2%. This number is based on the average estimate of 8 brokerage analyst(s). China-Biotics Inc. (NASDAQ:CHBT) is the 3rd fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 35.5%. This number is based on the average estimate of 2 brokerage analyst(s). BioMimetic Therapeutics, Inc. (NASDAQ:BMTI) is the 4th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 35.0%. This number is based on the average estimate of 1 brokerage analyst(s). Sinovac Biotech Ltd. (NASDAQ:SVA) is the 5th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 29.0%. This number is based on the average estimate of 1 brokerage analyst(s).

Acorda Therapeutics Inc. (NASDAQ:ACOR) is the 6th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 25.0%. This number is based on the average estimate of 1 brokerage analyst(s). EXACT Sciences Corporation (NASDAQ:EXAS) is the 7th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 25.0%. This number is based on the average estimate of 1 brokerage analyst(s). Incyte Corporation (NASDAQ:INCY) is the 8th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 25.0%. This number is based on the average estimate of 1 brokerage analyst(s). Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is the 9th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 25.0%. This number is based on the average estimate of 1 brokerage analyst(s). XenoPort, Inc. (NASDAQ:XNPT) is the 10th fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 25.0%. This number is based on the average estimate of 1 brokerage analyst(s).